Business context and reporting period
Important identity discrepancy: The supplied filing is for Trail One, Inc., a development-stage Nevada company—not Citius Pharmaceuticals, Inc. It covers the three months ended December 31, 2011, Trail One’s fiscal first quarter of 2012. Trail One planned to sell customized decorative automobile license-plate tags and had not begun sales.
Financial results and liquidity
| Metric | Quarter ended Dec. 31, 2011 | Quarter ended Dec. 31, 2010 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $2,196 | $8,995 |
| Interest expense | $372 | $13 |
| Net loss | $2,568 | $9,008 |
| Operating cash flow | $(2,196) | $(3,041) |
| Cash at period end | $216 | $959 |
At December 31, 2011, total assets were $216 and current liabilities were $26,625, including $20,693 in demand loans from the CEO and $1,076 of accrued related-party interest. Working capital and stockholders’ equity were each negative $26,409; accumulated deficit was $44,409. The related-party loans bear 8% interest. No interest or income taxes were paid during the quarter. No gross margin was reported because there were no sales.
Changes, outlook, and risks
Compared with the year-earlier quarter, operating expenses and net loss declined; cash at quarter end was also lower. The company reported no revenue in either period. Cash increased by $4 during the quarter, supported by $2,200 of additional related-party borrowing.
Management said existing liquidity was insufficient for operations and anticipated capital needs, and stated that additional financing was needed. It estimated a burn rate of about $2,620 per month, expected revenue would not cover expenses for at least the next 12 months, and sought additional capital, including equity or debt; the filing also cited a $75,000 funding need to complete its marketing program. Management warned that financing might not be available on acceptable terms or at all, and that failure to obtain funds could force the company to cease operations. The filing states that these conditions raise substantial doubt about the company’s ability to continue as a going concern.
The company had not placed definitive product orders, and its estimated retail price of about $150 and projected manufacturing, packaging, shipping, and marketing costs were not confirmed. Disclosure controls were deemed ineffective, citing lack of an independent board or audit committee, inadequate segregation of duties, and reliance on a financial consultant for financial reporting. The filing reported no material legal proceedings, defaults on senior securities, or off-balance-sheet arrangements. It also contains an inconsistent reference to revenue from “liquid gels,” despite describing a tag business.
Investor facts to verify
- Confirm the filing is the intended document: its registrant is Trail One, Inc., not Citius Pharmaceuticals, Inc.
- Confirm the intended reporting period: the filing is for the quarter ended December 31, 2011.
- Verify current cash, demand obligations to the CEO, and whether the company obtained financing after the filing.
- Assess the going-concern warning, ineffective disclosure controls, and the feasibility and costs of the proposed product launch.
- Clarify the filing’s inconsistent “liquid gels” reference and stated funding requirements.